Use of Follow-Up Psycho-Oncology Consultations in Urological Cancer after Transition from Inpatient to Outpatient Care
Oncology Research and Treatment · 2024
DOI: 10.1159/000542458 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Oncology Research and Treatment, 2024. Verfasst von Dominik Fugmann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Institute of Psychosomatic Medicine and Psychotherapy, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseld…. Hauptthemen laut MEDLINE: Urologic Neoplasms, Referral and Consultation, Ambulatory Care, Psycho-Oncology. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
In urological oncology, the physical and psychological effects of cancer and its treatment post-discharge highlight the importance of follow-up psycho-oncology consultations. This study examines their utilisation and identifies predictors in urological cancer patients after inpatient care.
Methods
A prospective, single-centre clinical observational study was conducted. Inpatients with urological cancer and ≥5 points on the Distress Thermometer and/or request for psycho-oncological support were recruited, offered an initial psycho-oncology consultation, and can attend up to five online or on-site appointments within 3 months of discharge. The following variables were collected: socio-demographics, psycho-oncological baseline documentation (PO-BADO), psychosocial distress (Distress Thermometer with problem list), anxiety and depressive symptoms (GAD-2 and PHQ-2), and performance status (ECOG).
Results
A total of 501 patients were screened, 139 were included, and 108 were analysed. Twenty five patients used psycho-oncological follow-up care (n = 16 online). The final hierarchical model predicting the use of follow-up psycho-oncological support included the two predictors: age (OR 0.93, 95% CI 0.90–0.96) and anxiety (OR 1.60, 95% CI 1.11–2.44).
Conclusion
Nearly 1 in 4 urological cancer patients use follow-up psycho-oncology consultations, mostly online. Predictors for this usage are younger age and higher levels of anxiety. To improve care, (1) online services reduce barriers; (2) older patients require support with these services; and (3) screening specifically for depression is crucial to ensure that follow-up appointments are scheduled as a mandatory part of hospitalisation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Institute of Psychosomatic Medicine and Psychotherapy, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Centre for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CI…
- Psychosomatic Medicine and Psychotherapy Clinic, LVR Clinic Düsseldorf, Düsseldorf, Germany.
- Department of Urology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Centre for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany.
Zitieren
APA
Fugmann, D., Holsteg, S., Schäfer, R., Kreuznacht, L., Speer, D., Niegisch, G., Dinger, U., & Karger, A. (2024). Use of Follow-Up Psycho-Oncology Consultations in Urological Cancer after Transition from Inpatient to Outpatient Care. Oncology Research and Treatment. https://doi.org/10.1159/000542458
Vancouver
Fugmann D, Holsteg S, Schäfer R, Kreuznacht L, Speer D, Niegisch G, et al. Use of Follow-Up Psycho-Oncology Consultations in Urological Cancer after Transition from Inpatient to Outpatient Care. Oncology Research and Treatment. 2024. doi:10.1159/000542458
BibTeX
@article{Fugmann2024,
author = {Fugmann, Dominik and Holsteg, Steffen and Schäfer, Ralf and Kreuznacht, Lars and Speer, Daniela and Niegisch, Günter and Dinger, Ulrike and Karger, André},
title = {Use of Follow-Up Psycho-Oncology Consultations in Urological Cancer after Transition from Inpatient to Outpatient Care},
journal = {Oncology Research and Treatment},
year = {2024},
doi = {10.1159/000542458}
}
EUVIMED